高级检索
当前位置: 首页 > 详情页

Pharmacological Effects and Mechanisms of Chinese Medicines Modulating NLRP3 Inflammasomes in Ischemic Cardio/Cerebral Vascular Disease

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]The Second Clinical School of Medicine Guangzhou University of Chinese Medicine Guangzhou 510405, P. R. China [2]State Key Laboratory of Quality Research in Chinese Medicine Faculty of Chinese Medicine Macau University of Science and Technology Macao 999078, Macao SAR of P. R. China [3]Guangdong Provincial Key Laboratory of Research on Emergency in TCM Guangdong Provincial Hospital of Chinese Medicine Guangdong 510405, P. R. China [4]Department of Immunology, School of Basic Medical Sciences Fudan University, Shanghai 200032, P. R. China
出处:
ISSN:

关键词: NLRP3 Inflammasome Cardiovascular Diseases Cerebrovascular Diseases Chinese Medicine Review

摘要:
Cardio/cerebral-vascular diseases seriously threaten human health and are the leading cause of death. As such, there is great interest in identifying a potential mechanism that controls the development process of cardio/cerebral vascular diseases. Present studies demonstrate that inflammasomes play an important role in the process of ischemic cardio/cerebral vascular diseases (ICCVDs). Among the pathological process of ICCVDs, inflammasomes activated the sterile inflammatory response that accelerated the development of diseases and aggravated the acute lesion of tissue. As the most thoroughly studied inflammasome, the NLRP3 inflammasome has been proven to be a potential therapeutic target for ICCVDs. In this review, we summarized the mechanisms of Chinese herbal medicine which can affect ICCVDs via the regulation of the NLRP3 inflammasome. Our study discovers that active compounds of Chinese medicines have a negative effect on NLRP3 in different ICCVDs models. Astragaloside IV may influence the receptor of the cell membrane to inhibit NLRP3 activation. Resveratrol, colchicinesis, salvianolic acid B, chrysophanol and sulforaphane may directly damage the formation of NLRP3 by inhibiting ASC or Caspase-1. Most of the active natural compounds can negatively regulate the downstream products of NLRP3 inflammasome such as IL-18 and IL1 beta. In addition, Chinese medicines such as sinomenine, ruscogenin, resveratrol, arctigenin and cepharanthineas may downregulate NLRP3 inflammasome by inducing autophagy activation. Due to the advantages of multi-target effects, Chinese herbal medicine can be treated as a splendid therapy for ICCVDs by inhibiting NLRP3 inflammasome.

基金:

基金编号: No. 2015A030313368 to D.W.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 2 区 全科医学与补充医学 3 区 医学:内科
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 全科医学与补充医学 2 区 医学:内科
JCR分区:
出版当年[2016]版:
Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]The Second Clinical School of Medicine Guangzhou University of Chinese Medicine Guangzhou 510405, P. R. China [2]State Key Laboratory of Quality Research in Chinese Medicine Faculty of Chinese Medicine Macau University of Science and Technology Macao 999078, Macao SAR of P. R. China
通讯作者:
通讯机构: [1]The Second Clinical School of Medicine Guangzhou University of Chinese Medicine Guangzhou 510405, P. R. China [2]State Key Laboratory of Quality Research in Chinese Medicine Faculty of Chinese Medicine Macau University of Science and Technology Macao 999078, Macao SAR of P. R. China [3]Guangdong Provincial Key Laboratory of Research on Emergency in TCM Guangdong Provincial Hospital of Chinese Medicine Guangdong 510405, P. R. China [*1]The Second Clinical School of Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510405, P. R. China. [*2]State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macao 999078, Macao SAR of P. R. China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号